418 related articles for article (PubMed ID: 10321503)
1. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.
Egorin MJ; Yuan ZM; Sentz DL; Plaisance K; Eiseman JL
Cancer Chemother Pharmacol; 1999; 43(6):445-53. PubMed ID: 10321503
[TBL] [Abstract][Full Text] [Related]
2. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Conley BA; Egorin MJ; Tait N; Rosen DM; Sausville EA; Dover G; Fram RJ; Van Echo DA
Clin Cancer Res; 1998 Mar; 4(3):629-34. PubMed ID: 9533530
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
Egorin MJ; Zuhowski EG; Sentz DL; Dobson JM; Callery PS; Eiseman JL
Cancer Chemother Pharmacol; 1999; 44(4):283-94. PubMed ID: 10447575
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tributyrin lipid emulsion with affinity to low-density lipoprotein: pharmacokinetics in adult male Wistar rats and cellular activity on Caco-2 and HepG2 cell lines.
Su J; He L; Zhang N; Ho PC
J Pharmacol Exp Ther; 2006 Jan; 316(1):62-70. PubMed ID: 16188956
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
Edelman MJ; Bauer K; Khanwani S; Tait N; Trepel J; Karp J; Nemieboka N; Chung EJ; Van Echo D
Cancer Chemother Pharmacol; 2003 May; 51(5):439-44. PubMed ID: 12736763
[TBL] [Abstract][Full Text] [Related]
14. Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice.
Eiseman JL; Yuan ZM; Eddington ND; Sentz DL; Callery PS; Egorin MJ
Cancer Chemother Pharmacol; 1996; 38(1):13-20. PubMed ID: 8603446
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics and oral bioavailability studies of columbianetin in rats after oral and intravenous administration.
Luo Q; Wang CP; Li J; Ma WF; Bai Y; Ma L; Gao XM; Zhang BL; Chang YX
J Ethnopharmacol; 2013 Oct; 150(1):175-80. PubMed ID: 23994338
[TBL] [Abstract][Full Text] [Related]
17. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ethylene glycol. I. Plasma disposition after single intravenous, peroral, or percutaneous doses in female Sprague-Dawley rats and CD-1 mice.
Frantz SW; Beskitt JL; Grosse CM; Tallant MJ; Dietz FK; Ballantyne B
Drug Metab Dispos; 1996 Aug; 24(8):911-21. PubMed ID: 8869828
[TBL] [Abstract][Full Text] [Related]
19. NTP toxicity studies of carisoprodol (CAS No. 78-44-4) administered by Gavage to F344/N rats and B6C3F1 mice.
Chan PC
Toxic Rep Ser; 2000 Aug; (56):1-G14. PubMed ID: 11986679
[TBL] [Abstract][Full Text] [Related]
20. Determination of tributyrin and its metabolite butyrate in Wistar rat plasma samples by gas chromatography/mass spectrometry.
Su J; Zhang N; Ho PC
Rapid Commun Mass Spectrom; 2004; 18(19):2217-22. PubMed ID: 15384139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
